1 results match your criteria: "Xuzhou Medical University Department of Hematology Xuzhou China.[Affiliation]"

Background: Although immunotherapies have greatly improved diffuse large B-cell lymphoma (DLBCL) prognosis, a proportion of patients remain to be relapsed or refractory. Therefore, the identification of novel therapeutic targets and drugs is urgently required. Inhibition of the bromodomain and extra-terminal (BET) proteins has been a promising therapeutic strategy for various haematologic cancers.

View Article and Find Full Text PDF